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Neurotoxic syndrome induced 
by clomipramine plus risperidone in a patient 
with autistic spectrum disorder: serotonin or 
neuroleptic malignant syndrome?
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Abstract 
To the best of our knowledge, there are no case studies of serotonin syndrome (SS) in patients with autism spectrum 
disorder. We report the case of a 33-year-old male who presented SS under the combined use of clomipramine and 
risperidone. More specifically, within 2 days after clomipramine (10 mg/BID-two times a day) was added to risperi-
done (4 mg/OD-once a day), mirtazapine 45 mg/OD and alprazolam (0,5 mg/TID-three times a day) he began to 
present mental, neurological and autonomic symptoms. All his psychopathological manifestations and laboratory 
findings normalized after the above-mentioned drugs’ discontinuation, and the administration of supportive medical 
care and lorazepam 2,5 mg/TID. The diagnosis of serotonin syndrome was challenging due to the relatively low dose 
of clomipramine, an increase of risperidone which had taken place before clomipramine administration and clinical 
symptoms which could be attributed to both serotonin and neuroleptic malignant syndrome.
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Background
Autism spectrum disorder (ASD) is a complex neurode-
velopmental disorder characterized by deficits in verbal 
and non-verbal communication and social functioning, 
restricted, repetitive or stereotypical patterns of interest 
and/or behaviour since the early developmental period. It 
is considered to constitute a continuum of heterogeneous 
life-long disorders, three or four times more prevalent in 
males than in females. [1].
Serotonin syndrome (SS) is characterized by cognitive 
and behavioural (e.g. confusion, agitation), autonomic 
(e.g. fever, diaphoresis, tachycardia) and neurological 
(e.g. myoclonus, rigidity) symptoms [2] and is a mani-
festation of overactivation of peripheral and central 
5-HT1A or 5-HT2A receptors [3]. Neuroleptic malig-
nant syndrome (NMS) is characterized by mental state 
changes, bradykinesia, rigidity, autonomic dysfunction 
and hyperthermia, and it is suggested to be caused by 
dopamine D2 receptor blockade [4, 5]. Both syndromes 
are uncommon, though life-threatening. However, SS is 
caused by increased intra-synaptic 5-HT levels, a condi-
tion of toxicity in which everyone is liable, whereas NMS 
is an idiosyncratic response.
Clomipramine blocks serotonin and also noradrenaline 
reuptake presumably increasing thus their neurotrans-
mission. It has been used in adult patients with ASD [6, 
7] with limited and conflicting evidence of effect, though 
well tolerated [8]. Furthermore, there are only scarce 
reports of risperidone—an atypical antipsychotic block-
ing dopamine D2 and serotonin 5HT2A receptors—in 
ASD patients which is usually administrated in doses 
ranging from 1 to 4 mg/day [9–11].
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Although dopaminergic and serotonergic neurotrans-
mission systems have been shown to be dysfunctional in 
autism [12, 13], to the best of our knowledge, no cases 
of SS have been reported in patients with ASD, whereas 
cases of NMS are very rare [14].
In the following, we report a patient with ASD who pre-
sented SS under the combined use of clomipramine and 
risperidone, mirtazapine and alprazolam and the diagno-
sis of SS was challenging due to the remarkable overlap 
between symptoms of both neurotoxic syndromes.
Case presentation
A 33-year-old male with ASD, without accompanying 
intellectual and language impairment and disorder sever-
ity level 1-requiring support [1] was admitted to our 
Department with psychomotor agitation, muscular rigid-
ity (neck, upper and lower extremities), cogwheel rigidity, 
sweating, pallor, tremor, hyperreflexia, clonus, delayed 
responsiveness, insomnia, oversalivation, bradykinesia 
and akathisia. The patient was extremely anxious with 
depressive mood, well orientated and did not have psy-
chotic symptoms. He had a body temperature of 37.9 °C, 
tachycardia of 129 beats/min and marginally elevated 
blood pressure (140/83  mmHg). Laboratory examina-
tion revealed elevated serum CPK: 3220  IU/L. Urine 
analysis and radiological investigations, including cranial 
computed tomography (CT), chest X-ray and abdominal 
sonography, were unremarkable. Thorough laboratory 
and clinical work-up did not reveal any signs of systemic 
infection.
Since his childhood, the patient had a long history of 
marked difficulties in peer, social and emotional interac-
tion, in developing and maintaining relationships, and 
suffered from extreme distress when exposed even to 
small life changes. At the age of eight, he was diagnosed 
as suffering from “Asperger syndrome with IQ within the 
normal range”. He was always viewed as eccentric with no 
sexual affairs. He studied journalism in a private college 
and he worked (in e-shops) only under the supervision 
from his father.
At the age of 18, he experienced a major depressive 
episode treated successfully with mirtazapine (30  mg/
OD-once a day). Since then, mirtazapine was adminis-
trated constantly at the same dose. Occasionally, risperi-
done was added at a low dose, no more than 2  mg/day 
and for about 1 month each time. Over the past month, 
he was unable to adapt to his working environment and 
had started feeling depressed and anxious about his 
physical and mental health. Then, alprazolam was added 
(0,5 mg/TID-three times a day), the dose of mirtazapine 
was increased to 45 mg/OD and risperidone was added 
gradually raised up to 4  mg/OD, within 2  weeks. Then 
and since the patient had no improvement, venlafaxine 
was started at the dose of 75  mg/OD but discontinued 
immediately after the first dosage due to the patient’s 
complaints of hand tremor and restlessness. One week 
later, after the patient having referred suicidal thoughts, 
clomipramine was added at the dose of 10 mg/BID-twice 
a day. Within 48  h, oversalivation, diaphoresis, anxi-
ety, muscular and neck stiffness, akathisia, dysphagia in 
liquids, fever (38.0  °C) ameliorated by paracetamol and 
gastrointestinal complaints had developed. Risperidone 
and clomipramine were discontinued and the patient 
was admitted to our Department. At the day of admis-
sion, he was taking alprazolam (0,5  mg/TID) and mir-
tazapine (45  mg/OD), both immediately discontinued 
and supportive medical care as well as lorazepam 2,5 mg/
TID was initiated. Within the following 10  days, mus-
cular symptoms improved and CPK levels decreased to 
83  IU/L (normal range 39–308). The patient’s psycho-
pathological state markedly improved, all laboratory 
parameters normalized and he was finally discharged 
4 weeks after admission.
Conclusions
The differential diagnosis of our case includes several 
alternatives: our patient fulfilled six of the Sternbach’s 
[15] SS criteria namely agitation, myoclonus, hyperre-
flexia, sweating, tremor, fever, and nine of Radomski’s 
[16], in addition to the above insomnia, akathisia, and 
tachycardia. However, the exclusion criterion of “a recent 
change in dosage of a neuroleptic agent” [15, 16] was 
also fulfilled. Indeed, risperidone alone could have led 
to NMS due to its antagonistic activity at both seroto-
nin and dopamine receptors. On the other hand, it had 
been administered to the patient several times in the past 
without producing such symptoms, nevertheless NMS is 
mainly an idiosyncratic rather than a dose-related phe-
nomenon [17]. The addition of clomipramine, which has 
a weak antagonistic effect at dopamine receptors and is 
a potent serotonin reuptake inhibitor, could have further 
contributed to dopamine hypoactivity [18]. The diagnosis 
of NMS could be possible given that our patient fulfilled 
three major Levenson’s criteria [19], namely fever, rigid-
ity and elevated creatine kinase, and two minor namely 
tachycardia and sweating. He also fulfiled one essential 
(administration of a neuroleptic drug), one major (ele-
vated CPK) and one minor (extrapyramidal symptoms) of 
Nierenberg’s NMS criteria [20].
Mirtazapine—an alpha 2 antagonist—which enhances 
central noradrenergic and serotonergic activity might 
have caused NMS or SS but the patient had tolerated it 
well for almost 15 years. Furthermore, fever, tachycardia 
and his marginally elevated blood pressure could have 
been attributed to the anticholinergic adverse effects of 
both risperidone and clomipramine.
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To put more emphasis on the distinction between the 
two syndromes, SS follows exposure to serotonin ago-
nists, develops within 24  h and resolves rapidly with 
treatment, as well as its main symptoms are altered men-
tal status, muscle rigidity, hyperreflexia, clonus, hyperki-
nesia, increased bowel sounds, and diaphoresis. On the 
other hand, NMS follows exposure to dopamine antago-
nists or rapid increase in dosage, develops more slowly 
within days or weeks and resolves with treatment in more 
than a week time, and it is characterized by cog-wheel or 
lead pipe rigidity, bradykinesia and extrapyramidal symp-
toms, encephalopathy, autonomic lability and hyperther-
mia [3, 4, 24]. Both SS and NMS share several common 
symptoms, besides it has been proposed that these syn-
dromes may share similar pathophysiology [22–24]. Nev-
ertheless, we consider as lending further support to SS 
diagnosis of our patient the relatively rapid escalation of 
symptoms within 24  h after clomipramine administra-
tion even in low dose, the presence of hyperreflexia, myo-
clonus and body temperature <380 C, as well as the lack 
of altered consciousness, severe autonomic and respira-
tory dysfunction, “lead pipe” rigidity and leukocytosis [2, 
16, 20, 21].
Furthermore, patient’s 2D6 isoenzyme might have 
been overloaded producing thus a state of serotonin 
toxicity. More specifically, co-medication of risperidone 
might have increased the plasma concentration of clomi-
pramine [25], whereas mirtazapine is not considered a 
potent inhibitor of 2D6 [26]. In addition, as Cano-Munoz 
et al. [27] have reported the co-administration of clomi-
pramine with alprazolam might potentially produce SS 
possibly due to the latter’s mild serotoninergic action. Of 
note, drug interactions that may increase the risk of SS 
development are the co-administration of serotoninergic 
antidepressants (SSRIs, MAOIs, SNRIs, TCAs), opiates 
with antidepressants, l-tryptophan or buspirone with 
SSRIs, or the latter with olanzapine and/or risperidone. 
Consequently, in our case, the co-administration of clo-
mipramine, which is among the most potent TCA sero-
tonin reuptake inhibitors, alongside with mirtazapine, 
risperidone and alprazolam may have contributed to SS 
development [3, 28]. At this point, it should be noted that 
elevated serotonin levels have been observed in autism 
[29].
With regard to the patient’s treatment, it was consisted 
of discontinuation of serotoninergic agents and risperi-
done, supportive care and lorazepam administration. In 
SS cases treatment with benzodiazepines is well tolarated 
and established in mild to moderate cases. Benzodiaz-
epines through their GABA-mimic action ameliorate 
patient’s agitation, mild hypertension, tachycardia and 
fever [2, 3, 28]. They are also considered as an advisable 
option in NMS cases. [22, 30].
Clinicians should be cautious about the development of 
SS in cases of clomipramine (even in low dose) and risp-
eridone co-administration in patients with ASD.
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